Cantor Fitzgerald Keeps a Buy Rating on Intercept Pharma (ICPT)


Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Intercept Pharma (ICPT) today and set a price target of $191. The company’s shares opened today at $102.60.

Young noted:

“: Reiterate Overweight, Increasing PT to $191/sh. Intercept reported 4Q earnings, but we thought the REGENERATE NASH safety update was very important too. We are increasing our PT to $191 from $170 after increasing our NASH from 75%. In light of recent pullback, which we think is unwarranted, Intercept is one of our top franchise picks. We think that the stock looks cheap relative to our conviction in REGENERATE. We believe that these data are clinically meaningful in advanced fibrosis and that titration will lower pruritus intensity. We think that risk/reward remains attractive into the full data update at EASL (April 10-14).”

According to TipRanks.com, Young is a 4-star analyst with an average return of 5.9% and a 48.8% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.

Currently, the analyst consensus on Intercept Pharma is a Strong Buy with an average price target of $161.80, a 57.7% upside from current levels. In a report issued on February 19, B.Riley FBR also reiterated a Buy rating on the stock with a $155 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $133.74 and a one-year low of $58.03. Currently, Intercept Pharma has an average volume of 829.3K.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Read More on ICPT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts